A Phase 4 interventional study of Everolimus and Tacrolimus in Renal Transplant, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-12-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant patients
162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.
This study's enrollment of 71 is below the median of 100 across 97 interventional studies indexed under Hypertrophy, Left Ventricular.
Browse Hypertrophy, Left Ventricular studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants continued with the same tacrolimus+Mycophenolic acid (MPA) (Myfortic® or Cell-Cept®) doses that were taken before study initiation (tacrolimus levels 4-7 ng/ml).
Drug: Tacrolimus · Drug: Mycophenolic acid (MPA)
Participants received an initial dose (day 1) of Everolimus (EVL) 2mg at night and tacrolimus (if taking Prograf®, a full dose of Prograf® in the morning and a 50% dose of Prograf® at night; if taking Advagraf®, a 75% dose in the morning. On days 2 and 3, participants took EVL 2 mg twice daily (bid) without tacrolimus. On days 4 and 5, the EVL dose was adjusted and levels maintained between 5-8 ng/mL. Participants also continued with their MPA doses that were taken prior to study initiation.
Drug: Everolimus · Drug: Tacrolimus · Drug: Mycophenolic acid (MPA)
Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
Also known as: Certican®
Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
Also known as: Prograf®, Advagraf®
Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
Also known as: Myfortic®, Cell-Cept®
Change From Baseline in Left Ventricular Mass Index (LVMI)
Left ventricular hypertrophy grade was assessed by echocardiogram where the left ventricular mass index was calculated. The presence of LVM was defined as \> 49.2 g/m\^2.7 in men and \>46.7 g/m\^2.7 in women. A negative change from baseline indicates improvement.
Time frame: Baseline, Month 24
Change From Baseline in Mean 24 Hour Systolic and Diastolic Blood Pressure
Blood pressure was measured using ambulatory blood pressure monitoring (ABPM). A negative change from baseline indicates improvement.
Time frame: Baseline, Month 6, month 12, month 24
Pulse Wave Velocity (PWV)
Utilizing the SphygmoCor Device, ECG leads placed at the carotid and femoral arteries provided the measure of the pulse wave at that particular arterial location. The distance between the two vascular beds divided by the pulse wave time shift provided a measure of the pulse wave velocity.
Time frame: Month 6, month 24
Percentage of Participants With Major Cardiovascular Events (MACE)
The percentage of participants who experienced MACE were reported. MACE included acute myocardial infarction, insertion or replacement of implantable defibrillator, peripheral vascular disorders, congestive heart failure, coronary artery bypass, other events, percutaneous coronary intervention and stroke.
Time frame: Month 24
Renal Function Measured by Serum Creatinine
Serum samples were collected to analyze serum creatinine.
Time frame: Month 6, month 12, month 24
Renal Function as Measured by Creatinine Clearance
Creatinine clearance was calculated using the Cockroft-Gault formula.
Time frame: Month 6, month 12, month 24
Renal Function as Measured by Estimated Glomerular Filtration Rate (eGFR)
Estimated GFR was caluclated using the modification of diet in renal disease (MDRD) formula.
Time frame: Month 6, month 12, month 24
Change From Baseline in Cardiovascular Biomarkers: Troponin I and Collagen Type 1 C-telopeptide (ICTP)
Blood samples were collected to analyze Troponin I and collagen type 1 C-telopeptide (ICTP). A negative change from baseline indicates improvement.
Time frame: Baseline, month 6, month 24
Change From Baseline in the Cardiovascular Biomarker, Glycosylated Hemoglobin (HbA1c)
Blood samples were collected to analyze HbA1c. A negative change from baseline indicates improvement.
Time frame: Baseline, month 6, month 24
Change From Baseline in the Cardiovascular Biomarker, Myeloperoxidase (MPO)
Blood samples were collected to analyze MPO. A negative change from baseline indicates improvement.
Time frame: Baseline, month 6, month 24
Change From Baseline in the Cardiovascular Biomarker, N-terminal Pro-brain Natriuretic Peptide Fraction (NT-proBNP)
Blood samples were collected to analyze NT-proBNP. A negative change from baseline indicates improvement.
Time frame: Baseline, month 6, month 24
Change From Baseline in the Cardiovascular Biomarker, Type 1 Procollagen Amino-terminal-propeptide (PINP)
Blood samples were collected to analyze PCR. A negative change from baseline indicates improvement.
Time frame: Baseline, month 6, month 24
Change From Baseline in Cardiovascular Biomarkers, C-reactive Protein (CRP)
Blood samples were collected to analyze CRP. A negative change from baseline indicates improvement.
Time frame: Baseline, month 6, month 24
Percentage of Participants With Biopsy-proven Acute Rejection (BPAR), Graft Loss, Death and Lost to Follow up
The incidence of BPAR, graft loss, death and lost to follow-up events was calculated using relative frequency.
Time frame: Month 24
| Milestone | Tacrolimus | Everolimus |
|---|---|---|
| Started | 36 | 35 |
| Safety set | 36 | 35 |
| Intent to treat (itt) set | 32 | 28 |
| Completed | 31 | 25 |
| Not completed | 5 | 10 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Exclusion criteria | 2 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Administrative problems | 0 | 1 |
| Withdrew: Serious adverse event | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 1 |
Left ventricular hypertrophy grade was assessed by echocardiogram where the left ventricular mass index was calculated. The presence of LVM was defined as \> 49.2 g/m\^2.7 in men and \>46.7 g/m\^2.7 in women. A negative change from baseline indicates improvement.
| g/m^2.7 | Tacrolimus | Everolimus |
|---|---|---|
| Change From Baseline in Left Ventricular Mass Index (LVMI) | -6.071 ± 20.116 | -4.008 ± 17.610 |
Blood pressure was measured using ambulatory blood pressure monitoring (ABPM). A negative change from baseline indicates improvement.
| mmHg | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=31,29) | -0.6 ± 9.1 | 3.2 ± 8.6 |
| Month 12 (n=28,24) | 2.1 ± 6.9 | 2.7 ± 10.4 |
| Month 24 (n=29,24) | 2.2 ± 10.6 | 2.0 ± 8.7 |
Utilizing the SphygmoCor Device, ECG leads placed at the carotid and femoral arteries provided the measure of the pulse wave at that particular arterial location. The distance between the two vascular beds divided by the pulse wave time shift provided a measure of the pulse wave velocity.
| m/sec | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=31,30) | 7.01 ± 1.62 | 7.40 ± 1.62 |
| Month 24 (n=28,25) | 7.58 ± 1.68 | 7.06 ± 1.74 |
The percentage of participants who experienced MACE were reported. MACE included acute myocardial infarction, insertion or replacement of implantable defibrillator, peripheral vascular disorders, congestive heart failure, coronary artery bypass, other events, percutaneous coronary intervention and stroke.
| Percentage of participants | Tacrolimus | Everolimus |
|---|---|---|
| Percentage of Participants With Major Cardiovascular Events (MACE) | 0.00 | 0.00 |
Serum samples were collected to analyze serum creatinine.
| mg/dl | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=33,29) | 1.232 ± 0.272 | 1.234 ± 0.360 |
| Month 12 (n=32,28) | 1.231 ± 0.278 | 1.256 ± 0.367 |
| Month 24 (n= 31,26) | 1.217 ± 0.235 | 1.260 ± 0.358 |
Creatinine clearance was calculated using the Cockroft-Gault formula.
| mg/min | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=29,25) | 64.841 ± 16.163 | 76.618 ± 27.708 |
| Month 12 (n=28,25) | 65.037 ± 15.866 | 73.363 ± 25.989 |
| Month 24 (n=28,24) | 66.933 ± 13.264 | 72.910 ± 23.926 |
Estimated GFR was caluclated using the modification of diet in renal disease (MDRD) formula.
| mL/min/1.73m^2 | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=33,29) | 55.648 ± 11.244 | 63.781 ± 18.380 |
| Month 12 (n=32,28) | 57.757 ± 11.391 | 61.225 ± 19.239 |
| Month 24 (n=31,26) | 57.727 ± 10.498 | 60.779 ± 17.023 |
Blood samples were collected to analyze Troponin I and collagen type 1 C-telopeptide (ICTP). A negative change from baseline indicates improvement.
| ng/ml | Tacrolimus | Everolimus |
|---|---|---|
| Troponin 1, Month 6 (n=27,30) | 0.000 ± 0.010 | -0.006 ± 0.026 |
| Troponin 1, Month 24 (n=24,24) | 0.003 ± 0.026 | -0.007 ± 0.018 |
| ICTP, Month 6 (n=27,30) | 0.049 ± 0.341 | -0.195 ± 0.234 |
| ICTP, Month 24 (n=24,24) | -0.035 ± 0.366 | -0.125 ± 0.323 |
Blood samples were collected to analyze HbA1c. A negative change from baseline indicates improvement.
| Percentage of HbA1c | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=20,22) | 0.015 ± 0.184 | 0.159 ± 0.346 |
| Month12 (n=22,20) | 0.045 ± 0.237 | 0.185 ± 0.407 |
Blood samples were collected to analyze MPO. A negative change from baseline indicates improvement.
| U/mL | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=27,30) | 0.433 ± 2.189 | -0.093 ± 1.158 |
| Month 24 (n=24,24) | -0.329 ± 0.280 | -0.642 ± 0.972 |
Blood samples were collected to analyze NT-proBNP. A negative change from baseline indicates improvement.
| pg/mL | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=27,30) | 21.604 ± 294.82 | -79.10 ± 401.44 |
| Month 24 (n=24,24) | -80.20 ± 424.24 | -193.3 ± 590.90 |
Blood samples were collected to analyze PCR. A negative change from baseline indicates improvement.
| ug/l | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=27,30) | -13.82 ± 34.110 | -33.36 ± 33.227 |
| Month 24 (n=24,24) | -13.65 ± 40.675 | -28.17 ± 30.381 |
Blood samples were collected to analyze CRP. A negative change from baseline indicates improvement.
| mg/dl | Tacrolimus | Everolimus |
|---|---|---|
| Month 6 (n=27,30) | 0.512 ± 2.342 | 0.326 ± 1.129 |
| Month 24 (n=24,24) | 0.100 ± 0.469 | -0.040 ± 1.683 |
The incidence of BPAR, graft loss, death and lost to follow-up events was calculated using relative frequency.
| Percentage of participants | Tacrolimus | Everolimus |
|---|---|---|
| BPAR | 0.00 | 0.00 |
| Graft loss | 0.00 | 0.00 |
| Deaths | 0.00 | 0.00 |
| Lost to follow-up | 3.13 | 0.00 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tacrolimus | — | 5/36 (13.9%) | 21/36 (58.3%) |
| Everolimus | — | 8/35 (22.9%) | 24/35 (68.6%) |
| Event | Tacrolimus | Everolimus |
|---|---|---|
| Drug hypersensitivityImmune system disorders | 0/36 | 1/35 |
| Oral herpesInfections and infestations | 0/36 | 1/35 |
| PneumoniaInfections and infestations | 0/36 | 1/35 |
| Respiratory syncytial virus infectionInfections and infestations | 0/36 | 1/35 |
| Septic shockInfections and infestations | 0/36 | 1/35 |
| UrosepsisInfections and infestations | 0/36 | 1/35 |
| Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/36 | 1/35 |
| HaematuriaRenal and urinary disorders | 0/36 | 1/35 |
| Renal impairmentRenal and urinary disorders | 0/36 | 1/35 |
| Urinary tract obstructionRenal and urinary disorders | 0/36 | 1/35 |
| Event | Tacrolimus | Everolimus |
|---|---|---|
| Urinary tract infectionInfections and infestations | 7/36 | 1/35 |
| Oedema peripheralGeneral disorders | 3/36 | 6/35 |
| ProteinuriaRenal and urinary disorders | 0/36 | 5/35 |
| HypertensionVascular disorders | 1/36 | 5/35 |
| Escherichia urinary tract infectionInfections and infestations | 4/36 | 4/35 |
| DiarrhoeaGastrointestinal disorders | 4/36 | 3/35 |
| AnaemiaBlood and lymphatic system disorders | 0/36 | 3/35 |
| Aphthous stomatitisGastrointestinal disorders | 0/36 | 3/35 |
| HypercalcaemiaMetabolism and nutrition disorders | 3/36 | 1/35 |
| LeukopeniaBlood and lymphatic system disorders | 0/36 | 2/35 |
| Age, Continuous(Years) | Tacrolimus | Everolimus | Total |
|---|---|---|---|
| Mean | 49.1 ± 12.0 | 47.4 ± 13.2 | 48.3 ± 12.5 |
| Sex: Female, Male(Participants) | Tacrolimus | Everolimus | Total |
|---|---|---|---|
| Female | 16 | 13 | 29 |
| Male | 20 | 22 | 42 |
The record gives a start of Aug 2010, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus
Hypertrophy, Left Ventricular →